Kite Pharma
News/ News/ Sales and Marketing
Appeals court reverses $1.2bn judgment against Gilead in BMS CAR-T case
Phil Taylor
Bristol-Myers Squibb, CAR-T therapies, Gilead Sciences, Juno Therapeutics, Kite Pharma, litigation, patent
0 Comment
Kite takes the ‘Appian way’ to off-the-shelf cell therapies for cancer
Phil Taylor
Appia Bio, cell therapy, Gilead Sciences, immuno-oncology, Kite Pharma, Oncology
0 Comment
BioNTech grows in cell therapies, buying Kite’s TCR platform
Phil Taylor
BioNTech, cell therapy, Gilead Sciences, immuno-oncology, Kite Pharma, M&A, Oncology
0 Comment
Gilead combs Shoreline for NK cell therapies in $2.3bn alliance
Phil Taylor
car-nk, cell therapy, Gilead Sciences, immuno-oncology, Kite Pharma, natural killer cell, Oncology, Shoreline Bioscience
0 Comment
ASCO21: Gilead sets up first FDA okay for CAR-T in adult ALL with Tecartus data
Phil Taylor
acute lymphoblastic leukaemia, ASCO 2021, CAR-T therapies, Gilead Sciences, Kite Pharma, Kymriah, Novartis, Oncology, Tecartus
0 Comment
Allogene set to disrupt CAR-T market with pivotal trial of ‘off the shelf’ therapy
Richard Staines
Allogene, CAR T, Gilead, Kite Pharma, non-Hodgkin lymphoma, Oncology
0 Comment
Oxford BioTherapeutics to research cell therapies for Gilead’s Kite
Phil Taylor
cell therapy, Gilead Sciences, immuno-oncology, Kite Pharma, Oncology, Oxford BioTherapeutics, partnership
0 Comment
Kite cues up first EMA okay for mantle cell lymphoma CAR-T
Phil Taylor
CHMP, ema, Gilead Sciences, Kite Pharma, mantle cell lymphoma, Non-Hodgkins Lymphoma
0 Comment